Sarepta Therapeutics, Inc. (SRPT) Deep Dive Video

Sarepta is a distressed DMD incumbent where FDA decisions on failed confirmatory data—and gene-therapy safety/competition—determine whether the stock is a renaissance rebound or a collapse.